Erley C M, Heyne N, Burgert K, Langanke J, Risler T, Osswald H
Department of Internal Medicine III, University of Tübingen, Germany.
J Am Soc Nephrol. 1997 Jul;8(7):1125-32. doi: 10.1681/ASN.V871125.
To evaluate therapeutic options for the prevention of radiocontrast media (RCM)-induced nephropathy, a model was developed in which rats received NG-nitro-L-arginine methyl ester (L-NAME) for 10 wk in order to inhibit nitric oxide (NO) synthetase. This study tests the hypothesis that infusion of an adenosine antagonist before RCM application may avoid the vasoconstrictive response in NO-depleted rats. Rats received L-NAME for 10 wk orally (50 mg/L drinking water) to achieve NO depletion. Renal function was determined by [3H]inulin clearance for analysis of the GFR and by flowmetry for assessing renal blood flow (RBF). After a control clearance period (baseline clearance period), the renal response to RCM application (sodium diatrizoate, 2 ml/kg body wt) was measured two times every 30 min starting 30 min after RCM application (clearance periods 1 and 2). L-NAME rats and control rats received two adenosine antagonists. The nonselective adenosine antagonist theophylline was given as an initial bolus of 50 mumol/kg body wt within 10 min, followed by continuous infusion of 100 mumol/kg body wt per h, and the specific adenosine A1-receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) was given as a bolus of 100 micrograms/kg body wt before RCM application. Results were compared with vehicle infusion. In the control group, no significant change of GFR or RBF could be detected after application of RCM with or without prior infusion of DPCPX or theophylline. In L-NAME rats, RBF decreased significantly after RCM application (baseline, 5.6 +/- 0.2 ml/min; first clearance period, 4.6 +/- 0.3 ml/min [P < 0.05]; second clearance period, 4.3 +/- 0.3 [P < 0.01]). GFR was also reduced in L-NAME rats without previous infusion of theophylline or DPCPX (baseline, 0.95 +/- 0.1 ml/min; first clearance period, 0.83 +/- 0.1 ml/min; second clearance period, 0.69 +/- 0.1 ml/min [P = 0.058]). Prior treatment with either theophylline or DPCPX resulted in complete protection against a decline of RBF and GFR induced by RCM in L-NAME rats. Rats with chronic NO blockade showed a significant increase of the renal vasoconstrictive effect of contrast media. Application of L-NAME in rats seems to constitute a suitable animal model to study the pathophysiology of radiocontrast media-induced nephropathy. In this animal model, administration of adenosine antagonists prevented the decline of GFR and RBF.
为评估预防放射性造影剂(RCM)诱发肾病的治疗方案,构建了一个模型,即大鼠接受NG-硝基-L-精氨酸甲酯(L-NAME)10周以抑制一氧化氮(NO)合成酶。本研究检验了以下假设:在应用RCM前输注腺苷拮抗剂可避免NO耗竭大鼠的血管收缩反应。大鼠口服L-NAME 10周(50 mg/L饮用水)以实现NO耗竭。通过[3H]菊粉清除率分析肾小球滤过率(GFR),并通过血流测量评估肾血流量(RBF)来测定肾功能。在对照清除期(基线清除期)后,在应用RCM(泛影酸钠,2 ml/kg体重)30分钟后开始,每30分钟测量两次肾脏对RCM应用的反应(清除期1和2)。L-NAME大鼠和对照大鼠接受两种腺苷拮抗剂。非选择性腺苷拮抗剂茶碱在10分钟内以50 μmol/kg体重的初始推注给药,随后以100 μmol/kg体重每小时持续输注,特异性腺苷A1受体拮抗剂8-环戊基-1,3-二丙基黄嘌呤(DPCPX)在应用RCM前以100 μg/kg体重推注给药。将结果与载体输注进行比较。在对照组中,无论是否预先输注DPCPX或茶碱,应用RCM后均未检测到GFR或RBF有显著变化。在L-NAME大鼠中,应用RCM后RBF显著下降(基线,5.6±0.2 ml/min;第一个清除期,4.6±0.3 ml/min [P<0.05];第二个清除期,4.3±0.3 [P<0.01])。在未预先输注茶碱或DPCPX的L-NAME大鼠中,GFR也降低(基线,0.95±0.1 ml/min;第一个清除期,0.83±0.1 ml/min;第二个清除期,0.69±0.1 ml/min [P = 0.058])。预先用茶碱或DPCPX治疗可完全保护L-NAME大鼠免受RCM诱导的RBF和GFR下降的影响。慢性NO阻断的大鼠造影剂的肾血管收缩作用显著增加。在大鼠中应用L-NAME似乎构成了一个研究放射性造影剂诱发肾病病理生理学的合适动物模型。在这个动物模型中,给予腺苷拮抗剂可防止GFR和RBF下降。